Market Overview

UPDATE: Citigroup Upgrades Express Scripts to Buy on Valuation

Share:
Related ESRX
Express Scripts Gains from Increased Generic Utilization
Andrew Left Predicts Eventual DOJ Prosecution Of Mallinckrodt For Selling HP Acthar Without Proven Efficacy

Citigroup raised its rating on Express Scripts (NASDAQ: ESRX) from Neutral to Buy and reiterated its $62 price target.

Citigroup commented, "We are upgrading Express Scripts to Buy as the recent sell-off offers a compelling opportunity on a valuation basis. ESRX shares in the last month have sold off 21% versus -4% for the S&P 500 and -2% for its largest PBM competitors CVS Caremark and Catamaran. We are adjusting our estimates that are now above consensus for 2013 and our $62 target price. With the shares trading at less than 12x our 2013 EPS estimate and near a decade-low valuation multiple, ESRX now offers a compelling 24% return to our target price."

Express Scripts closed at $50.05 on Wednesday.

Latest Ratings for ESRX

DateFirmActionFromTo
Apr 2017Edward JonesDowngradesBuyHold
Mar 2017Wells FargoDowngradesMarket PerformUnderperform
Nov 2016Deutsche BankUpgradesSellHold

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ESRX)

View Comments and Join the Discussion!